New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).

https://arctichealth.org/en/permalink/ahliterature175230
Source
CMAJ. 2005 May 10;172(10):1299
Publication Type
Article
Date
May-10-2005
Author
Jill Cotter
Eric Wooltorton
Author Affiliation
Department of Family Medicine, University of Ottawa, Ottawa, Ont.
Source
CMAJ. 2005 May 10;172(10):1299
Date
May-10-2005
Language
English
Publication Type
Article
Keywords
Canada
Cardiovascular Diseases - etiology
Clinical Trials as Topic
Cyclooxygenase Inhibitors - contraindications - therapeutic use
Decision Making
Drug Approval
Humans
Isoxazoles
Product Surveillance, Postmarketing
Pyrazoles - contraindications - therapeutic use
Risk factors
Sulfonamides - contraindications - therapeutic use
United States
United States Food and Drug Administration
Notes
Cites: N Engl J Med. 2005 Mar 17;352(11):1071-8015713944
Cites: N Engl J Med. 2005 Mar 17;352(11):1081-9115713945
Comment In: CMAJ. 2005 Oct 11;173(8):85216217096
Comment In: CMAJ. 2005 Oct 11;173(8):852-316217095
Comment In: CMAJ. 2005 Oct 11;173(8):85316217098
PubMed ID
15833921 View in PubMed
Less detail